linjc16/ctgov huggingface dataset:
Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk

Study Overview
=================
Brief Summary
-----------------
The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.

Official Title
-----------------
Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.

Conditions
-----------------
Iatrogenic Effect, Prescription, Follow-up, Consultation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient hospitalized in the geriatric medicine department Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization; Numerous therapeutic modifications (3 or more); Drug interaction or introction of a new drug with one or more drug interactions; Medicinal product with a narrow therapeutic marge drug requiring close monitoring. Exclusion Criteria: patient non hospitalized in the geriatric medicine department
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of side effect number in ederly with polymedicated drugs | Change of side effect number in ederly with polymedicated drugs | up to 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
iatrogenic, prescription, follow-up, consultation
Impella Supported OPCABG

Study Overview
=================
Brief Summary
-----------------
The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period

Official Title
-----------------
Impella-supported Off-pump Coronary Artery Bypass Grafting in High Risk Revascularizations: A Single Center Prospective Observational Study

Conditions
-----------------
Ischemic Cardiomyopathy

Intervention / Treatment
-----------------
* Device: Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Ejection fraction ≤ 35% Symptomatic three vessel Coronary Artery Disease with target vessels that are amenable to bypass (as determined by the operating surgeon) Adequate Distal target caliber (as determined by the PI) Exclusion Criteria: Exclusion criteria will include the existing contraindications to either Impella therapy or OPCABG revascularization: Patients with structural heart disease requiring cardiopulmonary bypass Patients with cardiogenic shock who require a period of short-term mechanical circulatory support Patients with mechanical aortic valve Patients with previous median sternotomy Patients with evidence of non-viability on preoperative cardiac MRI or CT scan Insufficient conduit BMI over 50 Patients who are COVID-19 positive at the time of screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.0 Device or Impella 5.5 with SmartAssist, followed by Impella supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative hemodynamic stability | Intraoperative hemodynamic stability, defined as mean arterial pressure (MAP), cardiac index (CI), central venous pressure (CVP), and cerebral perfusion as measured by NIRS maintained within normal ranges for the entire operative time except potentially for short periods not exceeding 10 minutes in total time. | Intraoperative |
A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis

Study Overview
=================
Brief Summary
-----------------
Pleurodesis is a technique used to fuse the two layers of the lining over the lung. This is done to get rid of collections of fluid or air in this space. A common reason would be cancer of the underlying lung or elsewhere causing fluid to collect in the pleural space. In this situation it is a palliative procedure to free the patient from symptoms like breathlessness.

Detailed Description
-----------------
Pleurodesis is a technique used to fuse the two layers of the pleura. This is done to prevent reaccumulation of collections of fluid or air in this space. Common indications are malignant pleural effusions, recurrent pneumothorax and even benign effusions which are otherwise difficult to eradicate.

Official Title
-----------------
A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis

Conditions
-----------------
Malignant Pleural Effusions, Recurrent Pleural Effusions, Primary Spontaneous Pneumothorax, Secondary Spontaneous Pneumothorax

Intervention / Treatment
-----------------
* Procedure: Pleurodesis with either talc or iodopovidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 12 years Symptomatic recurrent pleural effusion Pneumothorax needing pleurodesis Exclusion Criteria: Life expectancy <1 month Unwilling to give consent Empyema ICTD drain output >150 ml/d Presence of an airleak

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Pleurodesis with either talc or iodopovidone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success |  |  | 
| Failure |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death |  |  | 
| Pain by VAS |  |  | 
| Time to Pleurodesis |  |  | 
| Others |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pleurodesis, talc, iodopovidone
Media Effects Study on Health-Related Content

Study Overview
=================
Brief Summary
-----------------
A media lab study will be conducted to determine the mechanism by which podcasting may exert an effect. This study will examine both physiological (heart rate, skin conductance, etc.) and psychosocial (knowledge, perceived control, elaboration, etc.) measures in participants listening to a podcast on health versus reading health content on the Web. We hypothesize that podcasting will create a greater physiological response than the Web. There will also be more elaboration in the podcasting group. Podcasting will produce greater feelings of control. Changes in knowledge will be greater in the Web group.

Conditions
-----------------
Processing Health Information

Intervention / Treatment
-----------------
* Behavioral: electronic health information


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older Be willing to be randomized to either the podcast or Web condition Able to attend the intervention session Exclusion Criteria: Not living in the Chapel Hill area

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: podcast<br> | Behavioral: electronic health information<br>* Participants will receive weight loss information via 1 of 2 different mediums.<br>|
| Active Comparator: Web group<br> | Behavioral: electronic health information<br>* Participants will receive weight loss information via 1 of 2 different mediums.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physiological response |  | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychosocial response |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
weight loss, health information, e-health
A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System

Study Overview
=================
Brief Summary
-----------------
The Jetstream System is a commercially available rotating, aspirating, expandable catheter designed to remove atherosclerotic plaque and blood clots in the lower limbs. The purpose of this study is to use intravascular ultrasound (IVUS) during the interventional procedure to measure the amount of plaque and blood clots removed by the Jetstream System.

Official Title
-----------------
The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study

Conditions
-----------------
Peripheral Arterial Disease, Peripheral Vascular Disease

Intervention / Treatment
-----------------
* Device: Pathway Jetstream Atherectomy System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient is ≥ 18 years of age. The documented peripheral vascular disease is/are located in a superficial femoral, popliteal or tibial peroneal trunk arteries in the lower limb. The patient is an acceptable candidate for percutaneous intervention using the Jetstream G2 System in accordance with its labeled indications and instructions for use. The patient has been informed about the nature of the study and has provided informed consent. Exclusion Criteria: Patient has no distal runoff. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site. Patient is pregnant or nursing a child. Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G2 System. Patient has clinically significant abnormal ECG or blood test results or any other factor that would put the patient at increased risk if participating in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plaque Morphology |  | up to 12 month follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peripheral arterial disease, peripheral vascular disease
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

Study Overview
=================
Brief Summary
-----------------
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

Detailed Description
-----------------
Investigators will achieved the following data from the participants: Demographic Past medical/habitual history COVID-19 status and related risk factors Mucormycosis status and related risk factors Ocular examination and imaging Follow-up

Official Title
-----------------
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

Conditions
-----------------
COVID-19, Mucormycosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed case of Mucormycosis in COVID-19 pandemic Exclusion Criteria: People with acute or severely ill conditions that prevent them from ophthalmic examination. Patient, or legal representative opposing the pursuit of the research
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vision loss | Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors | Related risk factors for vision loss | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus Disease-Associated Mucormycosis, COVID-19, Rhino-orbital-cerebral mucormycosis, Mucormycosis
Safety and Performance of Short- and Long-term Baseplates for Attaching the Marco Recorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical investigation is to test the safety and performance of short- and longterm Baseplates constructed with different types of biocompatible adhesives.

Official Title
-----------------
Safety and Performance of Short- and Long-term Baseplates for Attaching the Marco Recorder

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Device: Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD
* Device: Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent obtained, and letter of authority signed before any study related activities Are at least 18 years of age and have full legal capacity Healthy skin behind the ear Exclusion Criteria: Pregnant or breastfeeding Known allergic responses to the adhesives Treatment with corticosteroids, either as a cream in the area behind the ear or systemically (tablet or injection) within the last month Subject is unable or does not have the necessary assistance to properly operate the device system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: crossover in first part, parallel in second part
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Short-term Baseplate<br> | Device: Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD<br>* Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear<br>|
| Active Comparator: Long-term Baseplate<br> | Device: Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480<br>* Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trans epidermal water loss (TEWL) to measure skin-friendliness | To evaluate the skin barrier functionality (i.e., skin-friendliness) after repeated use of two types of Baseplates (i.e., adhesives) on the skin behind the ear. | up to 35 days |
Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome

Study Overview
=================
Brief Summary
-----------------
Adding L-carnitine is more successful than clomiphene as a first line therapy for ovulation induction in women with clomiphene resistant PCOS

Detailed Description
-----------------
Patients younger than 35 years, presenting with primary or secondary infertility following regular intercourse for at least 1 year and diagnosed with PCO according to Rotterdam's criteria who had received five unsuccessful clomiphene citrate-timed intercourse stimulation cycles were included.

Official Title
-----------------
Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial

Conditions
-----------------
Treatment Resistant Disorders

Intervention / Treatment
-----------------
* Drug: l-carnitine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients younger than 35 years, presenting with primary or secondary infertility following regular intercourse for at least 1 year and diagnosed with PCO according to Rotterdam's criteria who had received five unsuccessful clomiphene citrate-timed intercourse stimulation cycles were included. The diagnosis was based on a complete history taking, physical examination and a paper documented complete infertility work-up within the previous 6 months, either conducted within the setting of the hospital or at a licensed infertility management clinic. Exclusion Criteria: age more than 40 years, tubal,uterine or male factor infertility

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: l-carnitine<br>adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene | Drug: l-carnitine<br>* 3gm l-carnitine from day 1 to day 12 of the menstrual cycle<br>* Other names: carivita,l-carnitol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ovulation induction | is to study the efficacy of l-carnitine in inducing ovulation in clomiphene resistant pco | 0ne year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy | the occurrence of pregnancy and the rate of continuation of pregnancy till end of the first trimester | 0ne year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
clomiphene resistant, pcos, induction of ovulation, l-carnitine